|
Fredrick L. Dunn, M.D. was the Head of Clinical Research for Metabolism and Endocrinology at Tularik, Inc, where he led the successful phase 2a “proof of concept” study for T-131 (now INT-131). At Tularik, he was responsible for the clinical development of a number of metabolic compounds in diabetes, obesity and dyslipidemia. Dr. Dunn has over 10 years of experience in the pharmaceutical industry, including positions at Novartis Pharmaceuticals as Global Head, Diabetes Clinical Research, and at Merck & Co as Executive Director, Academic and Professional Affairs. Prior to joining industry, Dr. Dunn served on the faculties of the Joslin Diabetes Center (Boston), Harvard Medical School and Duke University Medical Center. He received his medical degree from the University of Illinois at Chicago, and completed his residency in Internal Medicine and fellowship in Endocrinology and Metabolism at the University of Texas Southwestern Medical Center at Dallas. After the acquisition of Tularik by Amgen, Inc, Dr. Dunn returned to an academic position where he is currently Associate Professor of Internal Medicine at the University of Texas Southwestern Medical Center at Dallas. | 